About Professor Alan Boddy

I want to understand how to improve the use of medicines in cancer, so that patients get the right drug at the right dose to help them live longer and feel better.

I am a pharmacologist, with over 20 years of experience in designing and evaluating the results from clinical studies in children and adults with cancer. I use the tools of drug analysis and pharmacogenetics to understand sources of variability in patients, backed up by validated in vitro methods.

During my research in Newcastle I established a validated process for the pharmacological evaluation of novel drugs developed to treat cancer, including pharmacokinetic, pharmacogenetic and pharmacodynamic evaluations. In children with cancer, I founded a pharmacology research group that has developed to become a world-leader in the design of studies in children and has delivered a number of studies that have improved the treatment of children with cancer.

Arriving in Sydney in August 2014, I am looking forward to the many opportunities to build on my existing expertise and experience in cancer pharmacology.

Selected publications

1. Yule SM, Price L, McMahon AD , Pearson ADJ and Boddy AV. "Cyclophosphamide metabolism in children with non-Hodgkin's lymphoma." Clinical Cancer Research (2004) 10(2) 455-460.

2. AV Boddy, ER Plummer, R Todd, J Sludden, M Griffin, L Robson, J Cassidy, D Bissett, A Bernareggi, M Verrill, AH Calvert. "A phase I and pharmacokinetic study of paclitaxel poliglumex (PPX, XYOTAXTM), investigating both every 3-weekly and every 2-weekly schedules". Clinical Cancer Research 2005 11: 7834-7840.

3. D Jamieson, K Wilson, S Pridgeon, JP Margetts, RJ Edmondson, HY Leung, R Knox, AV Boddy "NQO1 & NQO2 activity and expression in bladder and ovarian cancer and lower NQO2 activity associated with an NQO2 exon 3 SNP" Clinical Cancer Research 2007: 13(5) 1584-1590.

4. AV Boddy, J Sludden, M J Griffin, C Garner, J Kendrick, P Mistry, C Dutreix, DR Newell and S.J. O'Brien. "Pharmacokinetic investigation of imatinib in patients with chronic myeloid leukaemia using accelerator mass spectrometry" Clinical Cancer Research 2007 13 (14): 4164-4169.

5. R Plummer, L Vidal, M Griffin, M Lesley, J de Bono, S Coulthard, J Sludden, LL Siu, EX Chen, AM Oza, GK Reid, AR McLeod, JM Besteman, C Lee, I Judson, H Calvert, AV Boddy. "Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors". Clinical Cancer Research 2009 15 (9): 3177-3183.

6. J Bray, J Sludden, MJ Griffin, M Cole, M Verrill, D Jamieson and AV Boddy, "Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide." British Journal of Cancer 2010 102: 1003-1009.

7. SE Rowbotham, NA Illingworth, AK Daly, GJ Veal, AV Boddy. "Role of UDP-glucuronosyltransferase isoforms in 13-cis retinoic acid metabolism in humans". 2010 Drug Metabolism and Disposition 38: 1211-1217.

8. Jamieson D, Cresti N, Bray J, Sludden J, Griffin MJ, Hawsawi NM, Famie E, Mould EVA, Verrill MW, May F, Boddy AV. Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy. Pharmacogenetics and Genomics (3.865) 2011, 21(12): 808-819.

9. Veal GJ, Errington J, Rowbotham SE, Illingworth NA, Malik G, Cole M, Daly AK, Pearson ADJ and Boddy AV. "Adaptive dosing approaches to the individualisation of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma" Clinical Cancer Research 2013 19: 469-479.

10.Hill CR, Cole M, Errington J, Malik G, Boddy AV, Veal GJ. "Characterisation of the clinical pharmacokinetics of Actinomycin D and the influence of ABCB1 pharmacogenetic variation on Actinomycin D disposition in children with cancer." Clinical Pharmacokinetics 2014 53: 741-751.